Allakos

Corporate Presentation

November 2023

Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease

Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. ("Allakos," the "Company," "we" or "our"); business strategy; plans and objectives for future operations; our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates; our expectations with regard to the initiation, design, timing and results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies; our preclinical, clinical and regulatory development plans for our product candidates, including the timing or likelihood of regulatory filings and approvals for our product candidates; the size of the market opportunity for our product candidates in the diseases we are targeting; and our expectations with regard to our ability to acquire, discover and develop additional product candidates and advance such product candidates into, and successfully complete, clinical studies, are forward-looking statements. Allakos has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. The words "anticipate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this presentation speak only as of the date of this presentation and are subject to a number of risks, uncertainties, and assumptions, including, but not limited to: the Company's stages of clinical drug development; the Company's ability to timely complete clinical trials for, and if approved, commercialize lirentelimab (AK002), the Company's ability to timely initiate clinical trials for AK006; the Company's ability to obtain required regulatory approvals for its clinical trials; uncertainties related to the enrollment of patients in its clinical trials; the Company's ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; Allakos' ability to obtain regulatory approvals to market its product candidates; market acceptance of the Company's product candidates; uncertainties related to the projections of the size of patient populations suffering from some of the diseases the Company is targeting; the Company's ability to advance additional product candidates beyond AK002; the Company's ability to obtain additional capital to finance its operations; general economic and market conditions; and other risks described in the "Risk Factors" section included in our periodic filings that we have made and will make with the Securities and Exchange Commission ("SEC"). In addition, Allakos operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Allakos' management to predict all risks, nor can Allakos assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements that Allakos may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Allakos does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Allakos' expectations, except as required by law.

Accuracy of Data: This presentation contains statistical data based on independent industry publications or other publicly available information, as well as other information based on Allakos' internal sources. We have not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information. Accordingly, Allakos makes no representations as to the accuracy or completeness of that data.

Additional Information: The Company has filed and will file Current Reports on Form 8-K, Quarterly Reports on Form 10-Q, and Annual Reports on Form 10-K, and other documents with the SEC. You should read these documents for more complete information about the Company. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.



Allakos Opportunity

Lirentelimab (anti-Siglec-8) inhibits mast cells and depletes eosinophils

Novel Targets

- AK006 (anti-Siglec-6) selectively and more potently inhibits mast cell activation, including KIT-mediated signaling
- Both lirentelimab and AK006 inhibit mast cell activation via multiple pathways

Significant Need for New Agents

- Lirentelimab targets large indications: Atopic Dermatitis and Chronic Spontaneous Urticaria
- Both lirentelimab and AK006 have potential to treat a broad range of serious, complex inflammatory diseases

Upcoming Data Catalysts and Expected Milestones


Milestones

- Late 4Q23 to 1Q24 Phase 2 Lirentelimab Data in Patients with Atopic Dermatitis
- Late 4Q23 to 1Q24 Phase 2b Lirentelimab Data in Patients with Chronic Spontaneous Urticaria
- 2Q24 Initiate a randomized, double-blind, placebo-controlled, CSU cohort in the Phase 1 Study of AK006





Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease






Leveraging the Native Inhibitory Function of Siglecs on Mast Cells

Activated State Siglec FceRI KIT ITIM motifs Mast Cell Activation

Mast cells can be activated by numerous receptors leading to mast cell degranulation and release of histamine, $TNF\alpha$ and other inflammatory mediators

Siglec-Mediated Inhibition




Activation of Siglec-6 or Siglec-8 with an agonistic antibody activates inhibitor machinery inside cell which attenuates activating signals



Lirentelimab Inhibits Mast Cells and Depletes Eosinophils


Lirentelimab (Anti-Siglec-8)

- Lirentelimab has been tested in three open-label trials in mast cell driven diseases:
 - Chronic Urticaria
 - Indolent Systemic Mastocytosis (ISM)
 - Severe Allergic Conjunctivitis (SAC)
- Lirentelimab treatment led to clinical activity in these indications
- Lirentelimab's mast cell inhibition is broad and inhibits mast cell activation via multiple pathways including IgE, IL-33, KIT, TLR-3, 7 & 8, TSLP and MRGPRX2
- Lirentelimab is currently being tested in two large, randomized, placebo-controlled trials





Lirentelimab Inhibits IgE-Mediated Mast Cell Activation






AK006 is Engineered for Deeper Mast Cell Inhibition

AK006 (Anti-Siglec-6)


- AK006 is a Siglec-6 mAb that selectively inhibits mast cells and reduces their numbers
 - Engineered for optimal mast cell inhibition
 - Reduces mast cells via ADCP in presence of activated macrophages
- AK006 is a more potent mast cell inhibitor
- AK006 mast cell inhibition is broad and inhibits mast cell activation via multiple pathways including IgE, IL-33, KIT, C5a and MRGPRX2
- The Phase 1 study of AK006 consists of single and multiple ascending doses administered in healthy volunteers, followed by a randomized, double-blind, placebo-controlled, CSU cohort






AK006 is a More Potent Mast Cell Inhibitor

IgE-Activated Human Tissue Mast Cells



- Human mast cells were activated with anti-FcεRI and treated with isotype, AK002 or AK006
- Human mast cells treated with AK006 displayed deeper inhibition than AK002 or isotype

KIT-mediated Mast Cell Activation Model in Siglec Transgenic Mice



- Siglec-6 and Siglec-8 transgenic mice were dosed with placebo control, isotype, AK002, or AK006 and then received recombinant stem cell factor (ligand for KIT) via intravenous injection
- Treatment with AK006 inhibited stem cell factor-induced mast cell activation to a greater extend than AK002



Program	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Milestone
Lirentelimab	Atopic Dermatitis						Topline expected late 4Q23 to 1Q24
(Anti-Siglec-8)	Chronic Spontaneous Urticaria						Topline expected late 4Q23 to 1Q24
AK006 (Anti-Siglec-6)	Healthy Volunteers & CSU						Expected initiation of CSU cohort in 2Q24
AK068 (Siglec-6/Siglec-8 Bispecific)	Inflammatory Diseases						Ongoing
T Cell Immunomodulatory Receptors	Inflammatory Diseases						Ongoing
AK007 (Anti-Siglec-10)	Immuno-Oncology						Ongoing



Significant Opportunity Exists to Treat Inflammation & Immunology

	Rheumatoid Arthritis	Psoriasis	Ulcerative Colitis	Crohn's Disease	Asthma	Atopic Dermatitis	Chronic Spontaneous Urticaria	Eosinophilic Gastrointestinal Disorders
2022 Estimated WW Sales	~\$27 bn	~\$24 bn	~\$7 bn	~\$16 bn	~\$7 bn	~\$7 bn	~\$1.8 bn	~\$0.1 bn
U.S. Prevalence Moderate-to Severe	1 million	1.2 million	350 thousand	700 thousand	≥1 million	5.5 million	2.0 million	500 thousand – 2 million
Market Maturity	Mature		More Mature		Less Mature		Immature	
FDA Approved Targeted Agents	<u>TNF-α: 6</u> <u>IL-6R: 2</u> <u>JAK: 3</u> <u>IL-1R: 1</u> <u>CD20: 1</u> <u>CD86: 1</u>	<u>TNF-α: 4</u> <u>IL-17: 3</u> <u>IL-23: 3</u> <u>IL12/IL-23: 1</u> <u>TYK2: 1</u> <u>PDE-4: 1</u>	<u>TNF-α: 3</u> JAK: 2 α4β7: 1 <u>IL12/IL-23: 1</u> <u>S1P: 1</u>	<u>TNF-α: 3</u> <u>α4β7: 2</u> <u>IL12/IL-23: 1</u> <u>IL-23: 1</u>	<u>IgE: 1</u> <u>IL-5: 3</u> <u>IL-4/IL-13: 1</u> <u>TSLP: 1</u>	<u>IL-4/IL-13: 1</u> <u>IL-13: 1</u> <u>JAK: 2</u>	<u>lgE: 1</u>	<u>IL-4/IL-13: 1</u>

Current Lirentelimab Clinical Development

Lirentelimab for Chronic Spontaneous Urticaria




Chronic Spontaneous Urticaria Overview

Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disease believed to be driven primarily by mast cells¹

CSU affects up to 3 million adults in the U.S., and 2 million managed by a specialist (allergist or dermatologist)^{2,3}

An estimated 800k adults with CSU are biologic-eligible, yet only ~10% of eligible patients are currently on a biologic^{3,4}

Xolair® (omalizumab) global CSU sales were estimated to be \$1.6 billion in 2021^5





Phase 2a Chronic Urticaria Study

Study Design

- Open-label study in patients with Chronic Urticaria (CU)
- Uncontrolled CU (UCT <12) at the time of enrollment
- Diagnosis of CU for at least three months, refractory to antihistamine treatment on 1 to 4x labeled dosage
- 45 patients 4 cohorts
 - Omalizumab-naïve Chronic Spontaneous Urticaria (CSU)
 - Omalizumab-refractory CSU¹
 - Cholinergic urticaria
 - Symptomatic Dermographism
- 6 monthly doses
- 0.3 mg/kg starting lirentelimab dose; increased to 1.0 mg/kg (dose 2 and 3); if UCT <12, increased to 3.0 mg/kg (dose 4, 5, and 6)

Endpoints

Primary Endpoint

 Change in Urticaria Control Test (UCT) Week 22 from Baseline

Key Secondary Endpoints


- Change in UAS7 (for CSU patients)
- Safety and tolerability



1.) Patients in the omalizumab refractory cohort had urticaria symptoms despite treatment with up to 600 mg (2x highest labeled dose) omalizumab for an average duration of 10 months.

Symptom Improvement by UAS7 with Lirentelimab in CSU

Chronic Spontaneous Urticaria



UAS7 is a validated patient-reported outcome recording the intensity of pruritus (Weekly Itch Severity Score, ISS7) and the number of wheals (Weekly Hives Severity Score, HSS7); each as weekly score range is 0 to 21. UAS7 total scores range from 0 to 42, with lower scores representing fewer symptoms (UAS7 0 = no itch or wheals; UAS7 42 = maximal itch and wheals).



SOURCE: Altrichter S et al. J Allergy Clin Immunol. 2022 May;150(3):736-737

Lirentelimab UAS7 Response in Omalizumab Naïve CSU


Endpoint	Baseline Week 0 (n=13 patients)	Omalizumab Naïve Week 22 (n=13 patients)
Average UAS7 Score	18.5	4.6 (-75%)
Patients with UAS7 \leq 6	0 (0%)	8/13 (62%)
Patients with UAS7 = 0	0 (0%)	7/13 (54%)
Patients with ISS7 = 0	0 (0%)	7/13 (54%)
Patients with HSS7 = 0	0 (0%)	10/13 (77%)

UAS7 is a validated patient-reported outcome recording the intensity of pruritus (Weekly Itch Severity Score, ISS7) and the number of wheals (Weekly Hives Severity Score, HSS7); each as weekly score range is 0 to 21 UAS7 total scores range from 0 to 42, with lower scores representing fewer symptoms (UAS7 0 = no itch or wheals; UAS7 42 = maximal itch and wheals).



SOURCE: Altrichter S et al. J Allergy Clin Immunol. 2022 May;150(3):736-737

61% Improvement in UAS7 in Omalizumab Refractory CSU Patients Who Received 6 Lirentelimab Doses



% Change in UAS7 - Omalizumab Refractory Patients (n=11)

1.) Last observation carried forward



SOURCE: Altrichter S et al. J Allergy Clin Immunol. 2022 May;150(3):736-737; Altrichter S, et al. EAACI 2019 Presentation.

Indication	UCT Baseline	UCT Week 22	UCT Complete Responders	PCE Response
Chronic Spontaneous Urticaria				
 Naïve (n=13) 	3.2	14.2	92%	-
 Xolair Refractory (n=7)¹ 	3.1	11.4	57%	-
Cholinergic Urticaria (n=11)	5.4	11.8	82%	100%
Symptomatic Dermographism (n=10)	5.7	9.1	40%	-

Urticaria Control Test (UCT) is a validated 4-item questionnaire that asks patients to retrospectively score four items, on a scale from 0 to 4, the impact of urticaria symptoms on morbidity, quality of life, quality of treatment, and overall disease control over the previous 4 Weeks. UCT ranges 0 to 16 (0=worst possible). UCT complete response: ≥3-point improvement from baseline and score ≥12.

Pulse Controlled Ergometry (PCE) Test utilizes a stationary bike or treadmill for the patient to trigger hives. Positive response = hives appearing <10 mins post start of sweating. Negative response (Responder) = no hives <10 mins post start of sweating

1.) Xolair refractory patients who received all 6 dose

SOURCE: Altrichter S et al. J Allergy Clin Immunol. 2022 May;150(3):736-737; Altrichter S, et al. EAACI 2019 Presentation.



7/7 (100%) Response Rate by PCE Test in CholU Patients

Cholinergic	Baseline	Week 22		
Patients	Response to Provocation ¹	Response to Provocation ¹		
CholU-1	+	-		
CholU-2	+	-		
CholU-3	+	-		
CholU-4	+	-		
CholU-5 ²	+	-		
CholU-6	+	-		
CholU-7	+	-		

AK002 increased trigger threshold in patients with Cholinergic Urticaria

Pulse Controlled Ergometry (PCE) Test utilizes a stationary bike or treadmill for the patient to trigger hives. Positive response = hives appearing ≤10 mins post start of sweating. Negative response (Responder) = no hives ≤10 mins post start of sweating

2. Bad osteoarthritis of knees, patient had warm damp cloth applied that caused wheals and itching. Patient terminated early, not due to any drug related AEs

SOURCE: Altrichter S et al. J Allergy Clin Immunol. 2022 May;150(3):736-737; Altrichter S, et al. EAACI 2019 Presentation

Phase 2b Chronic Spontaneous Urticaria Study

Study Design

- Multi-center, randomized, DB, placebo-controlled
- Active moderate-to-severe symptoms
- CSU diagnosis with onset ≥6 months prior to screening
- Diagnosis of CSU refractory to antihistamines
 - Presence of itch and hives despite current use of antihistamines
 - UAS7 score ≥16 and HSS7 score ≥8 at baseline
- Includes patients with prior biologics treatment
- 110 adult patients (1:1 randomization)
 - 300 mg Q2W subcutaneous lirentelimab (n=55)
 - Placebo (n=55)

Endpoints

Primary Endpoint

Change from baseline in UAS7 at week 12

Key Secondary Endpoints

- Absolute change in ISS7
- Absolute change in HSS7
- Proportion of patients with UAS7=0



Chronic Spontaneous Urticaria Landscape

Drug Name	MOA	UAS7 Response						Opportunity
Valair®	Anti-IgE mAb	Dose Group ¹	150 mg	300 mg	Place	ebo		
Xolair® (omalizumab)		UAS7	-14.4 (-48%)	-20.8 (-66%)	-8. (-26		•	>50% of patients continue to have symptoms Black box for anaphylaxis ¹
		UAS7=0	15%	36%	9%	6		
Durningent®		Dose Group ²	300	mg	Place	ebo		
Dupixent [®] (dupilumab)	Anti IL-4/IL-13R mAb	UAS7	-20.5 (•	-12.0 (-37%)		•	Q2W dosing No improvement in Xolair failures ³
			I		I		I	
	Anti KIT mAb	Dose Group ⁴	75 mg Q4W	150 mg Q4W	300 mg Q8W	Placebo		c-Kit is expressed on hematopoietic
Barzolvolimab		UAS7	-17 (-56%)	-23 (-75%)	-24 (-76%)	-10 (-35%)		stem cells, melanocytes, CNS and germ cells ⁵
		UAS7=0	23%	51%	38%	6%		gern eene
		Dose Group ⁶	25 m	a BID	Place	ebo		
Remibrutinib	BTK Inhibitor	UAS7	-20 8	& -20	-12 to -14			BTK is expressed on hematopoietic cells including B cells, myeloid cells, and platelets ⁷
		UAS7=0	(-65% 8 28% t	,	(-40% to -46%) 7% to 11%			including D cells, myelold cells, and platelets



Lirentelimab for Atopic Dermatitis



Atopic Dermatitis Overview

Atopic dermatitis (AD) is a chronic inflammatory skin condition in which mast cells and eosinophils may contribute to pathogenesis¹

AD affects 16 million adults in the U.S., and over 5 million are managed by a specialist (dermatologist or allergist)^{2,3}

An estimated 2 million adults with AD are biologic-eligible, yet only ~10% of eligible patients are currently on a $biologic^{3,4}$

Dupixent® (dupilumab) achieved an estimated \$5 billion in global AD sales in 2021^{4,5}

Approximately 2 million adult AD patients are eligible for a biologic in the U.S.

5.5 million adult AD pts managed by a specialist⁽²⁾

2.0m (36%)


moderate-to-severe and inadequately controlled with topical agents⁽²⁾

220k

Treated with Dupixent^(3,4) (~10% of biologiceligible patients)



Biopsies of Atopic Dermatitis Lesions Show Evidence of Mast Cell and Eosinophil Activity



n=13 biopsy-matched patients



Severe Allergic Conjunctivitis Phase 1b Study

Study Design

- Open-label study in patients with SAC
- Diagnosis of AKC, VKC or PAC
- Average total ACS score of 15 or more from <a>>14 daily questionnaires during 4-week screening
- 29 patients 3 cohorts
 - Atopic keratoconjunctivitis
 - Vernal keratoconjunctivitis
 - Perennial allergic conjunctivitis
- 6 monthly doses
- 0.3 mg/kg starting dose, followed by 1.0 mg/kg then either 1.0 mg/kg or 3.0 mg/kg, based on symptoms

Endpoints

Primary Endpoint


Safety and tolerability

Key Secondary Endpoints

- Allergic Conjunctivitis Symptom (ACS) PRO:
 - Itching, photophobia, foreign body sensation, ocular pain, and lacrimation
- Ocular Symptom Score (OSS) Investigator assessment:
 - Itching, redness, tearing, and chemosis
- Atopic comorbidities assessment:
 - Atopic dermatitis, asthma, rhinitis




Severe Allergic Conjunctivitis



Redness, Chemosis



Photophobia, Watering, Periorbital Swelling








Case Study: Reversal of Neovascular and Inflammatory Changes

Prior to Lirentelimab


After 3 Doses of Lirentelimab






Lirentelimab Reduced Clinically-Relevant Cytokines in Phase 1 Severe Allergic Conjunctivitis Study

Ocular Inflammation via Tear Cytokines






Improvements in Allergic Conjunctivitis Signs & Symptoms



Investigator Assessment

SOURCE: Anesi, S. et al. Journal of Allergy and Clinical Immunology 2022; Leonardi A, et al. EAACI 2020 Presentation

Lirentelimab Improved Atopic Dermatitis Symptoms in ENIGMA2 and SAC Studies



Allakos®

Patients with comorbid atopic dermatitis filled in a daily global disease severity questionnaire on a ten-point scale (scale of 0 to 10).

SOURCE: ENIGMA2 data on file, Post-hoc exploratory analysis; SAC Study prospective analysis from Anesi, S. et al. Journal of Allergy and Clinical Immunology 2022

Phase 2 Atopic Dermatitis Study Design

Study Design

- Multi-center, randomized, DB, placebo-controlled
- Chronic disease that has been present \geq 3 years
 - EASI score ≥16
 - − Involvement of \geq 10% of body surface area
 - IGA score ≥3
 - Inadequate control by topical treatments
- Includes patients with prior biologics treatment
- 130 adult patients (1:1 randomization)
 - 300 mg Q2W subcutaneous lirentelimab (n=65)
 - Placebo (n=65)

Endpoints

Primary Endpoint

 Proportion of patients who achieve eczema area and severity index (EASI)-75 at week 14

Key Secondary Endpoints

- Percent change in EASI from baseline to week 14
- Proportion of patients who achieve an IGA score of 0 or 1 AND a ≥2-point improvement in Investigator Global Assessment (IGA) at week 14



Atopic Dermatitis Landscape

Drug Name	ΜΟΑ	EASI-75 Response	IGA Response	Opportunity
Dupixent [®] (dupilumab)	Anti IL-4/IL-13R mAb	44% – 51% vs. 12 – 15% placebo ¹	36 – 38% vs. 9 – 10% placebo ¹	 >50% of patients continue to have symptoms Conjunctivitis in ~26%² Q2W dosing¹
Adbry™ (tralokinumab)	Anti IL-13 mAb	25% – 33% vs. 10% – 13% placebo ³	16 – 21% vs. 7 – 9% placebo ³	 >50% of patients continue to have symptoms Conjunctivitis in ~10%³ Q2W dosing³
Lebrikizumab	Anti IL-13 mAb	51% – 59% vs. 16% – 18% placebo ⁴	33% – 43% vs. 11% – 13% placebo⁴	 >50% of patients continue to have symptoms Conjunctivitis in ~10%⁴ Q2W dosing⁴
Rinvoq [®] (upadacitinib)	JAK Inhibitor	60% – 80% vs. 13% – 16% placebo ⁵	39% – 62% vs. 5% – 8% placebo ⁵	 Black box warnings for: major cardiac events, infections, malignancies⁵
Cibinqo™ (abrocitinib)	JAK Inhibitor	40% – 62% vs. 10% – 12% placebo ⁵	24% – 44% vs. 8% – 9% placebo ⁶	 Black box warnings for: major cardiac events, infections, malignancies⁶







Safety Summary


- Intravenous (IV) lirentelimab has been administered in >750 patients, and with >300 patients on treatment for one year or more
 - Most common adverse event has been infusion-related reactions (IRR)
 - IRRs commonly associated with IV administered ADCC antibodies
 - No long-term safety findings to date
- Subcutaneous (SC) lirentelimab is currently being used and will be used in all future studies
 - SC lirentelimab in Phase 1 healthy volunteers was well tolerated (n=36)
 - No injection site reaction or injection reactions
 - No treatment related adverse events
 - No serious adverse events



AK006: Siglec-6 mAb that Selectively and Potently Inhibits Mast Cells



AK006: Siglec-6 mAb That Inhibits and Depletes Mast Cells




AK006 is a humanized IgG1 agonistic Siglec-6 mAb that selectively inhibits mast cells and reduces their numbers:

- AK006 inhibits mast cell activation via multiple stimuli including IgE, IL-33, SCF, C5a, MRGPRX2 and others
- Reduction of mast cells via antibody dependent cellular phagocytosis (ADCP) in the presence of activated macrophages

The Phase 1 study of AK006 consists of single and multiple ascending doses administered in healthy volunteers, followed by a randomized, double-blind, placebo-controlled, CSU cohort



AK006 Potently Inhibits IgE-Mediated Mast Cell Activation



AK006 Inhibits IgE-Mediated Mast Cell Activation


in Human Tissue

AK006 Demonstrates Comparable IgE-Mediated Mast Cell Inhibition as BTK Inhibitor in Human Tissue

AK006 has potentially clinically meaningful mast cell inhibition



AK006 Protects Against Systemic Anaphylaxis in Humanized Mice




AK006 inhibits IgE-mediated mast cell activation in vivo



AK006 Inhibits KIT-Driven Mast Cell Activation

KIT-Driven Mast Cell Activation Mouse Model

p-STAT3 Imaging in KIT-Activated Human Mast Cells




AK006 reduces KIT-mediated MC activation via inhibition of STAT phosphorylation and translocation to the nucleus



AK006 Reduces Human Mast Cells via Antibody-Dependent Cellular Phagocytosis

In Vitro ADCP Assay




AK006 induces dual mechanism of mast cell inhibition and reduction



Ex Vivo Human Tissue Mast Cells


AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice





41

AK006 Phase 1 Trial



Allakos®

Financial Overview & Key Milestones



Balance Sheet and IP Protection

Cash, Cash Equivalents and Investments in Marketable Securities as of September 30, 2023	\$193.9 M
– 3Q23 Net Cash Used	\$27.2 M
Common Shares Outstanding as of September 30, 2023	87.5 M



First lirentelimab U.S patent to expire in 2035 without extensions



Manufacturing SC lirentelimab at 17K liter scale








Sustained Depletion of Blood Eosinophil Counts

Phase 2 ENIGMA1 Study and Open-Label Extension



SOURCE: Dellon ES, et al. New England Journal of Medicine. 2020;383:1624-1634.

a. Blood eosinophils collected just prior to each infusion

b. Inclusive of Lirentelimab exposure during the open-label portion of the Phase 2 ENIGMA 1 study

